Although there will be changes in the marketplace if the Supreme Court decision makes residents in states using HealthCare.gov ineligible for subsidies, it won't be anything that is irreversible, according to Thomas P. Miller, JD, resident fellow at the American Enterprise Institute.
The predictions of so-called "death spirals" in insurance markets in states on the federal exchange resulting from a Supreme Court decision in King v. Burwell for the plaintiffs may be overblown, according to Thomas P. Miller, JD, resident fellow at the American Enterprise Institute.
Although there will be changes in the marketplace if the Supreme Court decision makes residents in states using HealthCare.gov ineligible for subsidies, it won't be anything that is irreversible. Something will be done in the event of a decision favorable for King, whether it is the Obama administration reversing course or the state reviewing their options for exchanges.
"I think there will be a flurry of activity—after the first round of finger pointing and blame shifting in Congress—to actually being to work on something that neither side will have as their first choice but will end up being the compromise that they have to do because they don't have another alternative," Mr Miller said.
Bridging the Gaps: New Strategies for Preventing Cardiovascular Disease
July 31st 2025During the Addressing Cardiovascular Risk and Intervening Early webinar, experts discussed innovative strategies for cardiovascular disease prevention, emphasizing risk assessment, lifestyle changes, and collaborative care to improve patient outcomes.
Read More
Trends in Insulin Out-of-Pocket Costs and Use Disparities, 2008-2021
July 31st 2025Given trends in cost and use, insulin out-of-pocket cost reduction policies would be more efficient if they targeted members in high-deductible health plans with savings options and low-income patients.
Read More
The Legal Architecture of Psychedelic Therapy: Risks, Responsibilities, and Reimbursement Realities
July 30th 2025Key legal, ethical, and compliance considerations for managed care professionals navigating the evolving landscape of psychedelic-assisted therapy include regulatory risks, data privacy challenges, reimbursement limitations, and the need for culturally informed care models.
Read More